NASDAQ:CHRS

Coherus Biosciences Stock Forecast, Price & News

$17.59

+0.59 (+3.47 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$17.04

Now: $17.59▼

$17.78

50-Day Range

$16.56

MA: $18.28▼

$19.89

52-Week Range

$10.86

Now: $17.59▼

$23.03

Volume871,750 shs

Average Volume1.31 million shs

Market Capitalization$1.26 billion

P/E Ratio7.52

Dividend YieldN/A

Beta1.85

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Coherus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Coherus Biosciences has a forecasted upside of 70.6% from its current price of $17.59.
Amount of Analyst Coverage
Coherus Biosciences has only been the subject of 2 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Coherus Biosciences has received 398 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Coherus Biosciences has received 386 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Coherus Biosciences has received 50.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote “Outperform” if you believe CHRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Coherus Biosciences does not currently pay a dividend.
Dividend Growth
Coherus Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coherus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $307,786.00 in company stock.
Percentage Held by Insiders
Only 15.86% of the stock of Coherus Biosciences is held by insiders.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Coherus Biosciences are expected to decrease by -47.31% in the coming year, from $1.67 to $0.88 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Coherus Biosciences is 7.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 19.66.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coherus Biosciences is 7.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.27.
Price to Earnings Growth Ratio
Coherus Biosciences has a PEG Ratio of 4.76. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Coherus Biosciences has a P/B Ratio of 11.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.43 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CHRS

Previous Symbol

CUSIPN/A

CIK1512762

Webwww.coherus.com

Phone650-649-3530

Employees232

Debt

Debt-to-Equity Ratio1.88

Current Ratio5.21

Quick Ratio5.00

Price-To-Earnings

Trailing P/E Ratio7.52

Forward P/E Ratio10.53

P/E Growth4.76

Sales & Book Value

Annual Sales$356.07 million

Price / Sales3.53

Cash Flow$1.37 per share

Price / Cash Flow12.86

Book Value$1.50 per share

Price / Book11.73

Profitability

EPS (Most Recent Fiscal Year)$1.23

Net Income$89.83 million

Net Margins37.11%

Return on Equity139.51%

Return on Assets37.87%

Miscellaneous

Outstanding Shares71,470,000

Market Cap$1.26 billion

Next Earnings Date11/5/2020 (Confirmed)

OptionableOptionable

$17.59

+0.59 (+3.47 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions

How has Coherus Biosciences' stock price been impacted by Coronavirus?

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CHRS stock has increased by 10.8% and is now trading at $17.59.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Coherus Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Coherus Biosciences.

When is Coherus Biosciences' next earnings date?

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Coherus Biosciences.

How can I listen to Coherus Biosciences' earnings call?

Coherus Biosciences will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Coherus Biosciences' earnings last quarter?

Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.44. The biotechnology company had revenue of $135.67 million for the quarter, compared to analyst estimates of $100.33 million. Coherus Biosciences had a return on equity of 139.51% and a net margin of 37.11%.
View Coherus Biosciences' earnings history.

What price target have analysts set for CHRS?

8 brokers have issued 1-year price objectives for Coherus Biosciences' stock. Their forecasts range from $20.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $30.00 in the next year. This suggests a possible upside of 70.6% from the stock's current price.
View analysts' price targets for Coherus Biosciences.

Who are some of Coherus Biosciences' key competitors?

Some companies that are related to Coherus Biosciences include China Biologic Products (CBPO), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Fate Therapeutics (FATE), Twist Bioscience (TWST), Ablynx (ABLYF), Immunovant (IMVT), bluebird bio (BLUE), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX) and Sorrento Therapeutics (SRNE).
View all competitors.

What other stocks do shareholders of Coherus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus Biosciences' key executives?

Coherus Biosciences' management team includes the following people:

Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)
Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)
Dr. Peter K. Watler, Chief Technical Officer (Age 57)
Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)
Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64)

What is Coherus Biosciences' stock symbol?

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus Biosciences' major shareholders?

Coherus Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.99%), Peregrine Capital Management LLC (0.73%), Foundry Partners LLC (0.08%), State of Alaska Department of Revenue (0.08%), Assenagon Asset Management S.A. (0.07%) and Ziegler Capital Management LLC (0.05%). Company insiders that own Coherus Biosciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti.
View institutional ownership trends for Coherus Biosciences.

Which major investors are selling Coherus Biosciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Ziegler Capital Management LLC, Assenagon Asset Management S.A., and Foundry Partners LLC. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti.
View insider buying and selling activity for Coherus Biosciences.

Which major investors are buying Coherus Biosciences stock?

CHRS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., Louisiana State Employees Retirement System, Pacer Advisors Inc., Standard Life Aberdeen plc, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, and DNB Asset Management AS.
View insider buying and selling activity for Coherus Biosciences.

How do I buy shares of Coherus Biosciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Coherus Biosciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $17.59.

How big of a company is Coherus Biosciences?

Coherus Biosciences has a market capitalization of $1.26 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.

What is Coherus Biosciences' official website?

The official website for Coherus Biosciences is www.coherus.com.

How can I contact Coherus Biosciences?

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings